01
54-page Evidence Companion
Frameworks, interpretation guidance and 13 standardized profiles covering therapies selected for their current relevance, popularity or emerging evidence.
CURRENT · POPULAR · EMERGING
Read the evidence behind the therapies shaping body composition now.
The RecompSignal Evidence Companion is a 64-page research package built to help you compare what studies measured, understand evidence maturity and regulatory status, and see what remains uncertain.
13 in-depth profilesStudied-dose indexComparison toolsOne revised edition included
Secure Gumroad checkout · Instant digital delivery · 14-day refund period
Introductory price$19One-time purchase
WHAT YOU RECEIVE
One package. Four practical research tools.
02
Studied-Dose Research Index
Study regimens placed beside population, formulation, duration and outcome context—so a dose number is never mistaken for a personal protocol.
03
Comparison Quick Reference
A compact way to compare maturity, status, outcomes and important limitations without reducing therapies to one headline percentage.
04
Printable Research Worksheets
Structured prompts for checking the population, comparator, duration, endpoint, source type and unanswered questions behind a claim.
FEATURED RESOURCE
The studied dose is useful only when the study stays attached.
The index records doses used in cited research alongside the details that determine what those doses mean. It does not provide starting doses, titration schedules, preparation instructions or self-use guidance.
- Population and study setting
- Formulation and route used in research
- Study duration and measured outcomes
- Evidence source and important context
Research context—not a dosing recommendation.
Individual treatment decisions belong with a qualified clinician using the current approved labeling and a person’s medical circumstances.
THERAPY COVERAGE
Thirteen in-depth profiles chosen for relevance—not to inflate a count.
The first edition focuses on therapies readers are encountering now, programs drawing substantial interest, and emerging approaches that help explain where the field is moving.
Current benchmarks
Semaglutide · Tirzepatide · Orforglipron · Tesamorelin
Popular and closely watched
Retatrutide · CagriSema · MariTide · Survodutide
Emerging pathways
Eloralintide · Bimagrumab · Apitegromab · Trevogrumab combinations
Early human research
MOTS-c—presented with its registered-study limits and without inferring efficacy or a numerical regimen that has not been publicly disclosed.
Coverage is intentionally selective. RecompSignal prioritizes standardized depth, source labeling and claim boundaries over a long list of shallow summaries.
INSIDE THE COMPANION
Built to show the reasoning—not just the conclusion.
WHO IT IS FOR
For readers who want context before conclusions.
- People following weight-loss and body-composition research
- Readers comparing established and investigational therapies
- Professionals and creators who need organized source context
- Anyone who wants to separate measured outcomes from marketing claims
What it is not
This is not medical advice, a prescribing guide, a sourcing directory or a self-treatment manual. It does not provide individualized recommendations, preparation instructions, dose escalation, stacking or purchasing guidance.
PRODUCT DETAILS
Clear terms before you buy.
How current is the research?
The first edition has an evidence-review cutoff of September 20, 2026. Sources and regulatory status are dated so readers can distinguish the reviewed record from later developments.
Are future updates included?
Your purchase includes one complimentary revised edition released within six months. Delivery instructions will use the purchaser email address.
How is the package delivered?
Gumroad provides instant access to the complete ZIP and individual PDFs after checkout.
What is the refund policy?
Refund requests are available within 14 calendar days of purchase. Contact john@recompsignal.com from the purchaser email address. Approved refunds are processed through Gumroad. Applicable consumer rights remain unaffected. Review the complete purchase terms.
PREFER ONE FOCUSED TOOL?
Get the Studied-Dose Research Index on its own.
The standalone three-page index organizes the research regimens behind 13 current, popular and emerging therapies. Every dose stays beside the population, formulation, duration and evidence status that give it meaning.
- Three-page landscape PDF for screen or print
- Approved and investigational programs clearly separated
- Evidence reviewed September 20, 2026
- Research context—not personal dosing guidance
Get the standalone index — $10Or get the complete 64-page package above for $19.
$10One-time purchase
EVIDENCE BEFORE HYPE
Explore the current field with the study context intact.
Get the 64-page package, the featured Studied-Dose Research Index and the comparison tools for the introductory price of $19.
Instant delivery14-day refund periodOne revised edition included